Urine

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Diabetes, Tissue, Profile, Language, Ageing, Mouth, Heart, Enalapril, Hyperkalemia, Angiotensin, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Liver, Medical Subject Headings, Fungal infection, Marketing, European Commission, INN, Stomach, Allergy, Itraconazole, Saquinavir, ATC, Glass, Nelfinavir, Depression, Kidney disease, Bleeding, International, European, Megacolon, Disease, Urinary retention, Language, Muscle weakness, Urinary bladder, Inflammation, Nefazodone, Water, Peanut, Ulcerative colitis, Colitis, Ketoconazole, Ritonavir, Tablet, Hyperkinesia, Indinavir, CYP3A4, Xerostomia, Select, Committee, Urination, Patient, Liver disease, Atazanavir, Anatomy, Medicine, Clarithromycin, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Tissue, Profile, Diabetes, Language, Ageing, Heart, Enalapril, Angiotensin, Hyperkalemia, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Medical device

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Copper, Urine, Liver, Medical Subject Headings, Diarrhea, Marketing, Meal, Duodenitis, Roger Hawkins (drummer), DSM-IV codes, INN, Deficit spending, Metabolism, Stomach, ATC, Pain, Capsule, International, Tremor, Dysarthria, Ageing, Nausea, Language, Brain, Inflammation, Duodenum, European Medicines Agency, Wilson's disease, Dystonia, Select, Patient, Liver disease, Safety, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Awareness, Marketing, Basiliximab, European Commission, INN, Leukopenia, Risk, Post-transplant lymphoproliferative disorder, Kidney transplantation, Infection, MPA, ATC, Pneumonia, Urinary tract infection, International, Gastroenteritis, Cytomegalovirus, Mycophenolic acid, Language, Pyelonephritis, Ciclosporin, CD86, Cancer, Basal-cell carcinoma, Transplant, Select, Committee, Patient, Human, Dehydration, Risk management, Anatomy, Medicine, Anemia, Vomiting, IIA, CHMP, CD80, Rejection, Dentistry

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, Agency, INN, Infection, Allergy, ATC, Carbapenem, International, Cough, Nausea, Language, Urinary tract infection, European Medicines Agency, Cilastatin, Bloodstream infections, Imipenem, Select, Patient, Iron, Bacteria, Anatomy, Penicillin, Vomiting, IIA, Gram-negative bacteria, Medical device

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Marketing, Protein, Acetylcholine receptor, Autoantibody, INN, GMG, Immune system, Fatigue, Lower respiratory tract infection, Infection, ATC, Antibody, International, Disease, Nose, Language, Blood, Muscle weakness, Urinary tract infection, Medicine, B cell, Neonatal Fc receptor, European Medicines Agency, Acetylcholine, Select, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Gland, Medical Subject Headings, Diarrhea, Urine, Marketing, European Commission, Agency, INN, Risk, Vitamin D, ATC, System, International, European, Headache, Disease, Needle, Osteosarcoma, Hypoesthesia, Blood, Language, Calcium, Heart, Cancer, Pseudohypoparathyroidism, European Medicines Agency, Thigh, Select, Safety, Kidney, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Neck, Skin, Medical device

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

EVerZom: Therapeutic Ambition in Exosome Biotherapies

Retrieved on: 
Wednesday, December 13, 2023
Urine, RNA, Liver, Quality of life, Dicarboxylic acid, Protein, Partnership, NASH, IND, Big Pharma, Acute liver failure, Saliva, Crohn's disease, Regenerative medicine, Lung cancer, Diffusion, Blood, Doctor of Philosophy, Cirrhosis, Fistula, Accelerator, Exosome, Lipid, FedEx, CNRS, Engineering, EIC, Cell, Patient, Publication, Safety, Therapy, Pharmaceutical industry

Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.

Key Points: 
  • Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.
  • This revolutionary drug modality constitutes a new therapeutic era for acellular off the shelf therapeutics, opening up new opportunities in cell and gene therapy.
  • This platform addresses the entire technological value chain, from cell to patient: cell sourcing, exosome generation, engineering and formulation.
  • Leveraging its innovation platform, EVerZom’s ambition is to develop its pipeline of proprietary biotherapies in regenerative medicine, while building partnerships in several other indications.

Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC

Retrieved on: 
Monday, December 11, 2023
Phase, Drug resistance, Urine, Associate, Lung cancer, CRC, Medicine, Molecular genetics, MRD, Plasma, Colorectal cancer, Disease, Blood, NEJM, Liquid biopsy, Cetuximab, Liquid, Genentech, Publication, Patient, NSCLC, Medical imaging

This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).

Key Points: 
  • This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).
  • This study exemplifies Predicine's continued leadership in the realm of liquid biopsy technology innovation and MRD.
  • Consistent with the outcomes of the prior Phase 1 clinical trial, PredicineBEACON™ showcased remarkable biomarker results in the Phase 1b clinical trial of Divarasib Plus Cetuximab in CRC patients.
  • The enhanced antitumor activity observed in this study reinforces the clinical utility of liquid biopsy profiling in evaluating the Phase 1b clinical trial of combined therapy in CRC patients.